Showing results (331-340 of 341) with videos related to
Sort By:
Pageof 35
Nature Communications|April 8, 2022
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Hengrui Liu, Sho Iketani, Arie Zask, et al.JAMA Oncology|September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical TrialRobert Olson, Will Jiang, Mitchell Liu, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 16, 2013
Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorderDouglas R Stewart, Hilde Brems, Alicia G Gomes, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trialReno Eufemon Cereno, Benjamin Mou, Sarah Baker, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 15, 2026
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastasesRobert Olson, Mitchell Liu, Alanah Bergman, et al.International Journal of Radiation Oncology, Biology, Physics|April 11, 2025
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 TrialAiden Kooyman, Jee Suk Chang, Mitchell Liu, et al.International Journal of Radiation Oncology, Biology, Physics|January 14, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 TrialSarah Baker, Linden Lechner, Mitchell Liu, et al.Molecular Systems Biology|October 1, 2025
High-throughput 3D engineered paediatric tumour models for precision medicineMoonSun Jung, Valentina Poltavets, Joanna N Skhinas, et al.Journal of Medical Genetics|January 15, 2013
Heterogeneity of mutational mechanisms and modes of inheritance in auriculocondylar syndromeChristopher T Gordon, Alice Vuillot, Sandrine Marlin, et al.Nature Medicine|June 6, 2024
Precision-guided treatment in high-risk pediatric cancersLoretta M S Lau, Dong-Anh Khuong-Quang, Chelsea Mayoh, et al.Pageof 35